ARRY - Array BioPharma Inc Stock Price, Fair Value and News

11.95USD-0.28 (-2.29%)Market Closed

Market Summary

USD11.95-0.28

Market Closed

-2.29%

ARRY Alerts

1 major insider sales recently.

ARRY Stock Price

View Fullscreen

ARRY RSI Chart

ARRY Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

13.17

Price/Sales (Trailing)

1.15

EV/EBITDA

8.45

Price/Free Cashflow

8.41

ARRY Price/Sales (Trailing)

ARRY Profitability

Operating Margin

26.59%

EBT Margin

11.24%

Return on Equity

52.94%

Return on Assets

8.04%

Free Cashflow Yield

11.89%

ARRY Fundamentals

ARRY Revenue

Revenue (TTM)

1.6B

Rev. Growth (Yr)

-15.04%

Rev. Growth (Qtr)

-2.52%

ARRY Earnings

Earnings (TTM)

137.2M

Earnings Growth (Yr)

539.65%

Earnings Growth (Qtr)

-0.55%

Breaking Down ARRY Revenue

Last 7 days

9.5%

Last 30 days

-11.4%

Last 90 days

-7.4%

Trailing 12 Months

-41.8%

How does ARRY drawdown profile look like?

ARRY Financial Health

Current Ratio

2.48

Debt/Equity

2.55

Debt/Cashflow

0.35

ARRY Investor Care

Shares Dilution (1Y)

0.48%

Diluted EPS (TTM)

0.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.7B	1.8B	1.6B	1.6B
2022	905.7M	1.1B	1.5B	1.6B
2021	683.2M	764.8M	814.0M	853.3M
2020	704.1M	760.3M	816.5M	872.7M
2019	0	0	469.3M	647.9M
2018	0	0	0	290.8M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Array BioPharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 18, 2024	hostetler kevin g.	sold (taxes)	-164,331	10.97	-14,980	chief executive officer
Mar 22, 2024	hottinger tyson	sold (taxes)	-49,436	12.65	-3,908	chief legal officer
Mar 20, 2024	hostetler kevin g.	sold	-100,565	12.3	-8,176	chief executive officer
Mar 19, 2024	manning neil	sold (taxes)	-15,378	11.73	-1,311	chief operations officer
Mar 19, 2024	rose travis	sold (taxes)	-13,947	11.73	-1,189	chief revenue officer
Mar 19, 2024	hottinger tyson	sold (taxes)	-27,729	11.73	-2,364	chief legal officer
Mar 19, 2024	collins terrance l	sold (taxes)	-20,891	11.73	-1,781	chief human resources officer
Mar 19, 2024	hostetler kevin g.	sold (taxes)	-172,548	11.73	-14,710	chief executive officer
Mar 13, 2024	rose travis	sold (taxes)	-29,019	12.65	-2,294	chief revenue officer
Mar 05, 2024	rose travis	sold (taxes)	-5,726	14.14	-405	chief revenue officer

Which funds bought or sold ARRY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	sold off	-100	-193,000	-	-%
Apr 24, 2024	CUSHING ASSET MANAGEMENT, LP dba NXG INVESTMENT MANAGEMENT	sold off	-100	-1,401,120	-	-%
Apr 24, 2024	Catalyst Capital Advisors LLC	new	-	10,228	10,228	-%
Apr 24, 2024	Robeco Institutional Asset Management B.V.	sold off	-100	-44,033	-	-%
Apr 24, 2024	DekaBank Deutsche Girozentrale	added	269	1,473,000	2,124,000	-%
Apr 24, 2024	Assenagon Asset Management S.A.	added	25.29	270,698	2,688,570	0.01%
Apr 23, 2024	Gradient Investments LLC	sold off	-100	-118	-	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.3	-289,000	77,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-434,537	1,354,400	0.01%
Apr 22, 2024	PFG Investments, LLC	new	-	214,123	214,123	0.01%

Are Funds Buying or Selling ARRY?

Are funds buying ARRY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ARRY

No. of Funds

ARRY Alerts

1 major insider sales recently.

Unveiling Array BioPharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	electron capital partners, llc	5.4%	8,198,076	SC 13G
Feb 13, 2024	hill city capital, lp	5.85%	8,840,335	SC 13G/A
Feb 13, 2024	vanguard group inc	9.18%	13,886,457	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 24, 2024	blackrock inc.	11.6%	17,529,949	SC 13G/A
Nov 17, 2023	hill city capital, lp	5.14%	7,770,335	SC 13G
Feb 09, 2023	vanguard group inc	9.20%	13,841,925	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 08, 2023	invesco ltd.	3.5%	5,243,222	SC 13G/A
Jan 30, 2023	blackrock inc.	10.7%	16,134,994	SC 13G/A

Recent SEC filings of Array BioPharma Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	4	Insider Trading
Apr 10, 2024	ARS	ARS
Apr 10, 2024	DEF 14A	DEF 14A
Apr 10, 2024	DEFA14A	DEFA14A
Mar 28, 2024	3	Insider Trading
Mar 26, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 22, 2024	8-K	Current Report
Mar 21, 2024	4	Insider Trading
Mar 21, 2024	4	Insider Trading

Peers (Alternatives to Array BioPharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
FSLR	18.7B	3.3B	14.67%	-15.70%	22.51	5.64	26.70%	1981.03%
ENPH	14.5B	1.8B	-3.49%	-51.42%	52.47	7.92	-30.11%	-43.96%
MID-CAP
SEDG	3.2B	3.0B	-9.62%	-81.29%	94.24	1.09	-4.30%	-63.39%
RUN	2.2B	2.3B	-7.99%	-53.02%	-1.37	0.97	-2.65%	-1025.44%
SMALL-CAP
BEEM	91.4B	67.4M	-5.65%	-34.84%	-5.7K	1.4K	86.60%	18.40%
ARRY	1.8B	1.6B	-11.38%	-41.84%	13.17	1.15	-3.72%	2996.57%
SHLS	1.4B	488.9M	-27.99%	-60.66%	33.73	2.85	49.55%	-68.23%
SPWR	340.2M	1.8B	-24.51%	-86.03%	-3.38	0.22	14.74%	-307.59%
FTCI	56.5M	127.0M	-6.25%	-82.56%	-1.12	0.45	3.20%	49.51%
SUNW	1.7M	154.9M	-	-97.50%	-0.02	0.01	10.63%	-80.26%
ASTI	341.4K	458.3K	-76.92%	-60.87%	-0.02	0.75	-62.52%	13.59%

Array BioPharma Inc News

Latest updates

Array BioPharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Revenue	-2.5%	342	350	508	377	402	515	420	301	220	189	197	248	181	139	115	438	318	198	-
Cost Of Revenue	-0.8%	261	263	358	276	329	438	380	274	224	183	176	202	145	113	93.00	319	-	151	-
Gross Profit	-7.8%	81.00	87.00	150	101	73.00	77.00	40.00	27.00	-4.27	6.00	21.00	46.00	35.00	27.00	22.00	118	-	47.00	-
Operating Expenses	6.8%	50.00	47.00	54.00	54.00	57.00	59.00	53.00	65.00	16.00	25.00	21.00	31.00	38.00	32.00	21.00	17.00	-	19.00	-
S&GA Expenses	16.8%	44.00	37.00	40.00	38.00	38.00	39.00	29.00	45.00	23.00	18.00	15.00	25.00	21.00	12.00	11.00	12.00	-	10.00	-
EBITDA Margin	4.0%	0.17*	0.16*	0.17*	0.12*	0.08*	0.05*	-0.02*	-0.04*	0.00*	0.02*	0.04*	0.05*	0.14*	-	-	-	-	-	-
Interest Expenses	-21.9%	10.00	13.00	10.00	10.00	13.00	9.00	8.00	7.00	7.00	13.00	7.00	9.00	7.00	1.00	2.00	5.00	-	4.00	-
Income Taxes	-94.3%	0.00	7.00	22.00	10.00	14.00	10.00	-18.44	-14.70	-5.22	-5.36	-1.83	2.00	1.00	1.00	-5.80	23.00	-	6.00	-
Earnings Before Taxes	-22.8%	23.00	30.00	87.00	36.00	9.00	51.00	-23.46	-40.68	-27.13	-32.92	-7.35	6.00	-9.20	-5.81	-3.44	96.00	-	24.00	-
EBT Margin	13.4%	0.11*	0.10*	0.10*	0.04*	0.00*	-0.03*	-0.11*	-0.12*	-0.07*	-0.05*	-0.02*	-0.02*	0.09*	-	-	-	-	-	-
Net Income	-0.6%	23.00	23.00	65.00	26.00	-5.25	41.00	-5.02	-25.94	-21.90	-27.56	-5.52	5.00	-9.77	-7.23	2.00	74.00	-	18.00	-
Net Income Margin	30.9%	0.09*	0.07*	0.07*	0.03*	0.00*	-0.01*	-0.07*	-0.09*	-0.06*	-0.05*	-0.02*	-0.01*	0.07*	-	-	-	-	-	-
Free Cashflow	27.6%	89.00	69.00	15.00	42.00	94.00	102	-12.20	-52.45	-98.45	-32.78	-92.59	-42.72	104	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	-4.0%	1,707	1,779	1,853	1,779	1,706	1,734	1,819	1,784	1,143	770	617	586	656	552	676	800	924	510
Current Assets	-3.6%	832	863	908	867	831	871	902	816	852	485	325	288	375	265	-	-	620	174
Cash Equivalents	43.1%	249	174	156	148	134	63.00	51.00	49.00	368	116	18.00	19.00	108	27.00	38.00	103	361	41.00
Inventory	-25.0%	162	216	207	255	233	270	330	299	206	173	138	125	118	97.00	-	-	148	55.00
Net PPE	8.0%	32.00	30.00	31.00	26.00	23.00	20.00	18.00	17.00	11.00	10.00	10.00	10.00	10.00	10.00	-	-	11.00	11.00
Goodwill	2.1%	436	427	441	2.00	416	401	418	442	343	70.00	70.00	70.00	70.00	70.00	-	-	70.00	70.00
Liabilities	-5.7%	1,096	1,162	1,240	1,275	1,282	1,335	1,414	1,332	975	534	689	654	737	175	323	471	618	245
Current Liabilities	-16.2%	336	401	435	471	465	513	513	433	245	214	168	233	289	147	-	-	591	135
Long Term Debt	0.3%	661	659	702	706	720	725	794	778	711	299	494	392	424	-	-	-	-	59.00
LT Debt, Current	-44.6%	21.00	39.00	37.00	34.00	39.00	48.00	51.00	48.00	4.00	4.00	4.00	4.00	4.00	-	-	-	56.00	20.00
LT Debt, Non Current	0.3%	661	659	702	706	720	725	794	778	711	299	494	392	424	-	-	-	-	59.00
Shareholder's Equity	-6.9%	259	278	287	207	124	111	110	170	-69.20	1.00	-	-	-80.90	-	-	-	305	-
Retained Earnings	15.1%	-130	-153	-176	-241	-267	-262	-302	-297	-271	-250	-222	-216	-221	-	-	-	-	-
Additional Paid-In Capital	-15.5%	345	408	418	426	383	393	402	411	203	251	150	148	140	-	-	-	-	-
Shares Outstanding	0.1%	151	151	151	151	150	150	150	148	130	131	127	127	121	-	-	-	-	-
Float	-	-	-	2,898	-	-	-	1,552	-	-	-	1,981	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																			(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	31.2%	94.00	72.00	21.00	46.00	97.00	105	-10.67	-50.10	-97.35	-31.73	-91.96	-42.15	104	21.00	-47.32	-200	-	-	-
Share Based Compensation	-15.9%	3.00	3.00	5.00	3.00	3.00	4.00	3.00	5.00	2.00	2.00	2.00	8.00	2.00	1.00	1.00	2.00	-	-	-
Cashflow From Investing	-137.6%	-5.21	-2.19	-5.54	-3.88	-3.93	-2.79	-1.54	-376	-1.10	-1.05	-2.60	-10.57	-0.73	-0.34	-0.10	-0.17	-	-	-
Cashflow From Financing	61.6%	-17.32	-45.13	-15.55	-23.76	-24.71	-89.55	22.00	101	350	131	93.00	-36.59	-22.27	-31.89	-17.42	-57.69	-	-	-

ARRY Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 1,576,551	$ 1,637,546	$ 853,318
Cost of revenue:
Cost of product and service revenue	1,146,442	1,410,270	770,459
Amortization of developed technology	14,558	14,558	14,558
Total cost of revenue	1,161,000	1,424,828	785,017
Gross profit	415,551	212,718	68,301
Operating expenses:
General and administrative	159,535	150,777	80,974
Change in fair value of contingent consideration	2,964	(4,507)	2,696
Depreciation and amortization	38,928	84,581	9,372
Total operating expenses	201,427	230,851	93,042
Income (loss) from operations	214,124	(18,133)	(24,741)
Other (expense) income, net	(1,015)	2,789	(905)
Interest income	8,330	3,181	209
Legal settlement	0	42,750	0
Foreign currency transaction (loss) gain, net	(53)	1,155	0
Interest expense	(44,229)	(36,694)	(35,684)
Total other (expense) income	(36,967)	13,181	(36,380)
Income (loss) before income tax expense (benefit)	177,157	(4,952)	(61,121)
Income tax expense (benefit)	39,917	(9,384)	(10,718)
Net income (loss)	137,240	4,432	(50,403)
Preferred dividends and accretion	51,691	48,054	15,715
Net income (loss) to common shareholders, basic	85,549	(43,622)	(66,118)
Net income (loss) to common shareholders, diluted	$ 85,549	$ (43,622)	$ (66,118)
Income (loss) per common share
Basic (in dollars per share)	$ 0.57	$ (0.29)	$ (0.51)
Diluted (in dollars per share)	$ 0.56	$ (0.29)	$ (0.51)
Weighted average common shares outstanding
Basic (in shares)	150,942	149,819	129,984
Diluted (in shares)	152,022	149,819	129,984

ARRY Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 249,080	$ 133,901
Accounts receivable, net	332,152	421,183
Inventories	161,964	233,159
Income tax receivables	0	3,532
Prepaid expenses and other	89,085	39,434
Total current assets	832,281	831,209
Property, plant and equipment, net	31,886	23,174
Goodwill	435,591	416,184
Other intangible assets, net	350,396	386,364
Deferred income tax assets	15,870	16,466
Other assets	40,717	32,655
Total assets	1,706,741	1,706,052
Current liabilities
Accounts payable	119,498	170,430
Accrued expenses and other	70,211	54,895
Accrued warranty reserve	2,790	3,690
Income tax payable	5,754	6,881
Deferred revenue	66,488	178,922
Current portion of contingent consideration	1,427	1,200
Current portion of debt	21,472	38,691
Other current liabilities	48,051	10,553
Total current liabilities	335,691	465,262
Deferred income tax liabilities	66,858	72,606
Contingent consideration, net of current portion	8,936	7,387
Other long-term liabilities	20,428	14,808
Long-term warranty	3,372	1,786
Long-term debt, net of current portion	660,948	720,352
Total liabilities	1,096,233	1,282,201
Commitments and contingencies (Note 16)
Series A Redeemable Perpetual Preferred Stock: $0.001 par value; 500,000 shares authorized; 432,759 and 406,389 issued, respectively; liquidation preference of $493.1 million and $493.1 million, respectively	351,260	299,570
Stockholders’ equity
Preferred stock $0.001 par value - 4,500,000 shares authorized; none issued at respective dates	0	0
Common stock $0.001 par value - 1,000,000,000 shares authorized; 151,242,120 and 150,513,104 shares issued at respective dates	151	150
Additional paid-in capital	344,517	383,176
Accumulated deficit	(130,230)	(267,470)
Accumulated other comprehensive income	44,810	8,425
Total stockholders’ equity	259,248	124,281
Total liabilities, redeemable perpetual preferred stock and stockholders’ equity	$ 1,706,741	$ 1,706,052

About Array BioPharma Inc

Array Technologies, Inc. manufactures and sells ground-mounting tracking systems used in solar energy projects in the United States, Spain, Brazil, Australia, and internationally. The company operates in two segments, Array Legacy Operations and STI Operations. Its products include DuraTrack HZ v3, a single axis tracker; Array STI H250 to deliver a lower levelized cost of energy with tracker system; Array OmniTrack; and SmarTrack, a software product that uses site-specific historical weather and energy production data in combination with machine learning algorithms to identify the optimal position for a solar array in real time to enhance its energy production. The company was founded in 1989 and is headquartered in Albuquerque, New Mexico.

CEO	Mr. Kevin G. Hostetler
WEBSITE	https://arraytechinc.com
INDUSTRY	Solar
EMPLOYEES	1096

Array BioPharma Inc Frequently Asked Questions

What is the ticker symbol for Array BioPharma Inc? What does ARRY stand for in stocks?

ARRY is the stock ticker symbol of Array BioPharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Array BioPharma Inc (ARRY)?

As of Wed Apr 24 2024, market cap of Array BioPharma Inc is 1.85 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARRY stock?

You can check ARRY's fair value in chart for subscribers.

What is the fair value of ARRY stock?

You can check ARRY's fair value in chart for subscribers. The fair value of Array BioPharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Array BioPharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARRY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Array BioPharma Inc a good stock to buy?

The fair value guage provides a quick view whether ARRY is over valued or under valued. Whether Array BioPharma Inc is cheap or expensive depends on the assumptions which impact Array BioPharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARRY.

What is Array BioPharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, ARRY's PE ratio (Price to Earnings) is 13.48 and Price to Sales (PS) ratio is 1.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARRY PE ratio will change depending on the future growth rate expectations of investors.